Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Inclusion Criteria: * Patients who have elected to undergo, or who have undergone (within 8 weeks) a surgical procedure that results (at minimum) in the absence of both ovaries * Patients enrolled in the screening arm of GOG-0199 who decide to undergo surgery are potentially eligible for GOG-0215 * Baseline bone mass density (BMD) T-Score ? -1.5 (no more than 1.5 standard deviation below the mean value for young adults) on both the total lumbar spine (L1-L4 region, not individual bones) and bilateral hip * Patients who had/have at least 1 intact ovary at the time of surgery are eligible * No prior distant metastatic malignant disease within the past 5 years * Patients treated for stage M1 (any T, any N) diagnosis in the past 5 years are ineligible * Patients who achieved a complete response after treatment for rM0 (any T, any N) within the past 5 years are eligible * Premenopausal\* * Last menstrual cycle occurred \< 12 months prior to study enrollment * GOG performance status 0-2 * Creatinine clearance \> 60 mL/min * No clinical or radiological evidence of existing fracture of the lumbar spine or bilateral hip * No history of hip of spine fracture with low-intensity trauma or not associated with trauma * No uncontrolled seizure disorder associated with falls * No diseases that influence bone metabolism, including any of the following: * Paget?s disease * Osteogenesis imperfecta * Uncontrolled thyroid or parathyroid dysfunction within 12 months prior to study entry * No other nonmalignant systemic disease, including any of the following: * Uncontrolled infection * Uncontrolled type 2 diabetes mellitus * Cardiovascular, renal, hepatic, or lung disease that would prevent prolonged follow-up * History of thrombosis or thromboembolism allowed * No known HIV positivity * No known hypersensitivity to zoledronate or other bisphosphonates * No psychiatric, psychological, or other conditions that prevent fully informed consent * No other active malignancy except nonmelanoma skin cancer * No history of any medical condition that places the patient at risk for donating blood for research purposes (e.g., chronic infectious diseases, sever anemia, or hemophilia) * Not pregnant * Negative pregnancy test * No current active dental problems, including any of the following: * Infection of the teeth or jawbone (maxilla or mandible) * Dental or fixture trauma * Current or prior diagnosis of osteonecrosis of the jaw * Exposed bone in the mouth * Slow healing after dental procedures * No recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction or implants) * No prior treatment for osteoporosis * No adjuvant radiotherapy within the past 31 days * No chemotherapy within the past 30 days * No prior surgery to the hip or spine * No prior systemic sodium fluoride for \> 3 months during the past 2 years * No more than 30 days use in the past 12 months and no concurrent tamoxifen, raloxifene, or any other selective estrogen-receptor modulator (SERM) * More than 12 months since prior and no concurrent endocrine therapy * Insulin and/or oral antidiabetic medications allowed * Thyroid hormone replacement allowed * More than 12 months since prior and no concurrent estrogen or hormone replacement therapy (estrogen plus progesterone or estrogen alone) * Prior or concurrent oral contraceptives allowed * Systemic (oral) hormone replacement therapy following surgery not allowed * Vaginal (non-systemic) estrogen allowed * More than 12 months since prior and no concurrent oral or IV bisphosphonate * More than 12 months since prior and no concurrent anabolic steroids or growth hormone * More than 12 months since prior and no concurrent systemic corticosteroids * Concurrent short term corticosteroid therapy (to prevent/treat chemotherapy-induced nausea/vomiting) allowed * More than 6 months since prior and no concurrent Tibolone * More than 2 weeks since prior and no concurrent drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate) * No concurrent chemotherapy or radiotherapy * No concurrent aromatase inhibitors * Concurrent enrollment on protocol GOG-0199 allowed